THE MODERN BIOHEALTH, WITH PERSPECTIVE.
Clinician-led care in Florida

MODERN BIO / CURRENT SAFETY & REGULATORY WATCH

UPDATED NOVEMBER 18, 2026

Safety alerts,
without the noise.

Exact products. Exact identifiers. Primary sources.

We separate recalls and regulatory facts from evidence, emerging technology and marketing—so you can see what changed and what it actually means.

20 SAFETY ALERTS5 REGULATORY WATCHES

HOW TO USE THIS PAGE

Match the product first.
Then contact the right person.

A recall applies to the product, lot, strength and expiration listed in its notice—not automatically to every product in the same category. If you think you have an affected product, verify its label and contact the dispensing pharmacy, manufacturer or clinician for guidance.

01 / CURRENT SAFETY ALERTS

What changed—and
who needs to check.

FDA-POSTED COMPANY RECALLNOV 13
2026
HIGH PRIORITY

TWO-LOT RECALL / UNDECLARED MILK ALLERGEN

OsteoDenx dietary supplement

bioQuad Life Sciences recalled two lots because the label did not declare that the product contains lactoferrin derived from cow's milk.

People with a milk allergy or severe sensitivity could have a serious or life-threatening reaction. The product was sold nationwide through bioquad.com, Amazon, resellers and a dental clinic from November 1, 2024 through November 11, 2026.

LOT 1
0524100 · expiration 05/2027
LOT 2
0625041 · expiration 08/2028
STANDARD UPCS
30 count: 8 57294 00722 8 · 60 count: 8 57294 00734 1
AMAZON UPCS
30 count: 8 57294 00725 9 · 60 count: 8 57294 00724 2
WHAT TO DO

Check the product name, package size, UPC, lot and expiration. If they match and you have a milk allergy or sensitivity, follow the company's return or replacement instructions and contact a clinician or pharmacist for individualized guidance. Trouble breathing, throat swelling, faintness or another severe reaction requires emergency care.

What remains known and unknown: No illnesses had been reported to the company as of November 13. The notice does not state how many units were distributed or whether the label was corrected for later production. The recall applies to the named products and lots, not to every calcium, bone-health or lactoferrin supplement.

FDA-POSTED COMPANY RECALLNOV 12
2026
HIGH PRIORITY

ONE-BATCH RECALL / HIDDEN DRUG INGREDIENT

Candy Power For Man Organic Honey

Eros Apothecary recalled one batch after FDA testing found undeclared tadalafil.

The product was sold through eBay from April 27 through July 20, 2026. It contains 60 individually wrapped candies in yellow-and-orange packaging. Tadalafil is a prescription PDE5 inhibitor that can interact with nitrate medicines such as nitroglycerin and lower blood pressure to dangerous levels.

BATCH
241020
MANUFACTURED
January 2024
EXPIRATION
December 2029
UPC
5285002251390
WHAT TO DO

Match the product name, batch, expiration and UPC and follow the company's recall instructions. Contact a qualified clinician or pharmacist if you used the product or are concerned about an interaction—especially if you use nitrate medication or have cardiovascular risk factors. Seek urgent care for severe symptoms.

What remains known and unknown: The FDA-posted company notice does not report an adverse-event total, the number of units sold or the tadalafil amount found. The recall applies to this named product and batch; it does not establish the contents of every honey or sexual-enhancement supplement.

FDA DRUG SAFETY COMMUNICATIONNOV 09
2026
HIGH PRIORITY

CLASS-WIDE LABEL CHANGE / RARE EYE CONDITION

GLP-1 medicines and potential NAION risk

FDA is requiring every marketed GLP-1 receptor agonist to add a warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION.

NAION is a rare optic-nerve condition that can cause sudden, painless loss or reduction of vision in one eye and may result in permanent vision loss. FDA says cases have been reported with all currently marketed GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, lixisenatide, exenatide, orforglipron and the dual GIP/GLP-1 medicine tirzepatide.

FDA ACTION
Warnings and Precautions label update
TRIAL ANALYSIS
126 randomized controlled trials
GLP-1 GROUP
6.4 cases per 100,000 person-years
COMPARATOR GROUP
3.8 cases per 100,000 person-years
WHAT TO DO

Contact a healthcare professional right away for sudden, painless vision loss or reduction in one eye, a new blind spot or tunnel vision, distorted colors, or a new blurry or hazy area. Medication decisions—including what to do after a suspected or confirmed NAION event—should be made with the treating clinician.

What remains known and unknown: FDA concluded that there is a potential increased risk, not that NAION is common or that every event is caused by the medicine. Its Sentinel analysis found no statistically significant increase versus SGLT2 inhibitors but did find an increase versus DPP-4 inhibitors. FDA found no mechanism in the animal data, and diabetes, high blood pressure, sleep apnea, anemia, kidney disease and smoking can independently raise NAION risk.

FDA-POSTED COMPANY RECALLOCT 30
2026
HIGH PRIORITY

ONE-LOT RECALL / DIETARY SUPPLEMENT

365 Whole Foods Market Ashwagandha capsules

Vitality Works recalled one lot of 120-count Standardized + Full Spectrum Blend Ashwagandha capsules because of potential Salmonella contamination.

The product was sold nationwide at Whole Foods Market stores and online through Amazon from November 24, 2025 through October 20, 2026. The company identified the potential contamination through routine sampling of one retail unit.

LOT
2025-26227
EXPIRATION
10/13/2028
UPC
9948252099
PACKAGE
120-count white bottle

Salmonella can cause fever, diarrhea, nausea, vomiting and abdominal pain. Infection can be more serious in young children, older adults and people with weakened immune systems.

WHAT TO DO

Check the brand, bottle size, UPC, lot and expiration printed on the bottom of the bottle. If they match, follow the recall instructions in the FDA-posted announcement. Contact a clinician if you used the product and have symptoms or are at higher risk for serious infection; severe symptoms require prompt medical evaluation.

What remains known and unknown: No illnesses had been reported to the company as of October 30. The notice does not establish how many bottles were sold or whether testing found contamination in additional units. The recall applies only to the named product and lot, not to every ashwagandha supplement.

FDA PUBLIC NOTIFICATIONOCT 28
2026
HIGH PRIORITY

HIDDEN DRUG INGREDIENTS / PAIN PRODUCT

RX7 Articulaciones

FDA laboratory analysis found undeclared diclofenac and dexamethasone in a product promoted for joint and muscle pain.

Diclofenac is an NSAID associated with risks including heart attack, stroke, gastrointestinal bleeding, ulcers and perforation. Dexamethasone is a corticosteroid that can suppress immune function and affect blood sugar, muscles and mental health.

PRODUCT
RX7 Articulaciones
FOUND BY FDA
Diclofenac + dexamethasone
LOT / EXPIRATION
Not provided
STATUS
Public notification; no recall named
WHAT TO DO

FDA says people taking this product should consult a healthcare professional promptly so corticosteroid-withdrawal risk can be assessed and use can be discontinued safely. Do not try to manage that risk alone. Seek urgent medical care for severe symptoms.

What remains unknown: FDA's notice does not identify a manufacturer, lot, expiration, distribution total or adverse-event count. The warning applies to the named product; FDA also notes that it cannot test every product marketed as a supplement or conventional food.

FDA PUBLIC NOTIFICATIONOCT 28
2026
HIGH PRIORITY

HIDDEN DRUG INGREDIENTS / PAIN AND ALLERGY PRODUCT

Ort-Flx

FDA laboratory analysis found undeclared diclofenac, dexamethasone and methocarbamol in a product promoted for pain, arthritis and allergies.

In addition to the NSAID and corticosteroid risks, methocarbamol can cause drowsiness, dizziness and low blood pressure, which can make driving or operating machinery unsafe.

PRODUCT
Ort-Flx
FOUND BY FDA
Diclofenac + dexamethasone + methocarbamol
LOT / EXPIRATION
Not provided
STATUS
Public notification; no recall named
WHAT TO DO

FDA says people taking this product should consult a healthcare professional promptly so corticosteroid-withdrawal risk can be assessed and use can be discontinued safely. Do not try to manage that risk alone. Seek urgent medical care for severe symptoms.

What remains unknown: FDA's notice does not identify a manufacturer, lot, expiration, distribution total or adverse-event count. The warning applies to the named product and does not establish the contents of every pain or arthritis supplement.

FDA PUBLIC NOTIFICATIONOCT 27
2026
HIGH PRIORITY

HIDDEN INGREDIENT / WEIGHT-LOSS PRODUCT

demograss Premier

FDA laboratory analysis found undeclared phenolphthalein in a product promoted for weight loss.

Phenolphthalein is not an active ingredient in any FDA-approved drug in the United States. FDA says studies suggest that it may increase cancer risk.

PRODUCT
demograss Premier
FOUND BY FDA
Phenolphthalein
LOT / EXPIRATION
Not provided
STATUS
Public notification; no recall named
WHAT TO DO

Follow FDA's advice not to purchase or use the named product. If you have taken it or are concerned about a reaction, contact a qualified clinician or pharmacist for individualized guidance. Seek urgent medical care for severe symptoms.

What remains unknown: FDA's notice does not identify a manufacturer, lot, expiration, distribution total, exposure level or adverse-event count. The finding applies to the named product; it does not mean every weight-loss supplement contains phenolphthalein.

FDA-POSTED COMPANY RECALLOCT 24
2026
HIGH PRIORITY

ALL-LOTS RECALL / HIDDEN DRUG INGREDIENTS

Ultimate Forza Male Supplement capsules

Tonight We Ride, LLC recalled all lots after testing found undeclared sildenafil, tadalafil and dapoxetine.

The products were sold through certain independently owned GNC franchise locations in the United States from 2017 through October 1, 2026. The company announcement posted by FDA says the affected products were not sold through GNC corporate stores.

MULTI-CAPSULE / BOX
Item 810208 · UPC 868592000002
SINGLE PACK
Item 810222 · UPC 868592000040
LOTS / EXPIRATION
All lots · no expiration listed
ADVERSE EVENTS
None reported to the company as of October 24

Sildenafil and tadalafil are prescription PDE5 inhibitors. When undeclared, they can expose someone to drug effects and interactions without informed clinical review; FDA highlights the risk of dangerously low blood pressure when either is combined with nitrate medicines such as nitroglycerin. Dapoxetine is not FDA-approved in the United States, and its safety and effectiveness for this product have not been established.

WHAT TO DO

Match the product name, configuration, item number and UPC. Follow the company's recall and return instructions, and contact a qualified clinician or pharmacist if you have used the product or are concerned about a reaction—especially if you take nitrate medication or have cardiovascular risk factors. Seek urgent medical care for severe symptoms.

What remains unknown: The notice does not provide expiration dates, the number of units sold or the number of tested samples. No reported adverse events does not establish that the product is safe. The recall applies to the named Ultimate Forza products and all lots; it does not apply automatically to every sexual-wellness supplement.

FDA-POSTED COMPANY RECALLNOV 12
2026
HIGH PRIORITY

ALL-LOTS RECALL / HIDDEN DRUG INGREDIENTS

10 Day Forecast

Game Changer Products, LLC recalled all lots and expiration dates after FDA testing found undeclared sildenafil and acetaminophen.

The 3200 mg capsules were sold nationwide—including Puerto Rico, Guam and the Northern Mariana Islands—through the company website, eBay and one Minnesota retailer from October 2021 through October 17, 2026. Sildenafil can interact with nitrate medicines such as nitroglycerin and lower blood pressure to dangerous levels. Unrecognized additional acetaminophen exposure can cause liver damage or failure and, less commonly, anaphylaxis or serious skin reactions.

PRODUCT
10 Day Forecast · 3200 mg capsules
FOUND BY FDA
Sildenafil + acetaminophen
LOT / EXPIRATION
All lots · all expiration dates
UPC
191645852717

WHAT TO DO

Match the product name and UPC and follow the company's recall instructions. If you used it—especially if you take nitrate medication, have cardiovascular risk factors or may have taken other acetaminophen-containing products—contact a qualified clinician or pharmacist for individualized guidance. Seek urgent medical care for severe symptoms.

What remains known and unknown: No adverse events had been reported to the company as of November 12. The notice does not identify the number of units sold, the ingredient amounts found or which lots were tested. All lots and expiration dates are included in the recall.

FDA + DEA NOTICEOCT 14
2026
HIGH PRIORITY

PUBLIC-HEALTH WARNING / CONCENTRATED OPIOID PRODUCTS

Concentrated 7-OH and mitragynine pseudoindoxyl products

FDA is warning about concentrated 7-hydroxymitragynine, commonly labeled 7-OH or 7-hydroxy, and the related substance mitragynine pseudoindoxyl, or MGPI. These opioid-active products are sold online and in gas stations, smoke shops and other retail outlets as tablets, gummies, shots, powders and products described as botanical or kratom-derived.

On October 14, DEA published a notice of intent to issue a temporary Schedule I order for 7-OH and MGPI above specified concentration or composition thresholds. This is a proposed temporary-control step—not the final scheduling order.

REGULATORY STATUS
Notice of intent; final temporary order not yet issued
SOLID THRESHOLD
More than 1 mg per gram
LIQUID THRESHOLD
More than 1 mg per milliliter
ALTERNATE TEST
Mitragynine-to-7-OH/MGPI ratio below 100:1
WHAT TO DO

Do not treat “botanical,” “kratom” or “supplement” branding as proof that a concentrated 7-OH or MGPI product is safe. FDA advises consumers not to use products labeled as 7-OH. If you use one regularly, are concerned about dependence or have had a reaction, contact a qualified clinician, pharmacist or poison-control service for individualized guidance. Trouble breathing, extreme sedation or unresponsiveness requires emergency care.

What remains known and unknown: DEA says a temporary order may be published on or after November 13, 2026. The existing August 26 Schedule I control for MGPI remains in effect until it expires or is replaced. HHS and DEA expressly state that the new thresholds do not establish that below-threshold products are safe. The action is designed to distinguish intentionally enhanced or concentrated products from products with trace alkaloid amounts; it is not an approval of kratom or any 7-OH product.

FDA-POSTED COMPANY RECALL / CATCH-UPOCT 07
2026
HIGH PRIORITY

ONE-LOT RECALL / PREWORKOUT SUPPLEMENT

RAPTURE Preworkout powder

Leader Formulas, LLC recalled lot 260327-4 after FDA testing found 1,3-dimethylamylamine, or DMAA.

The 450 g round containers have red-and-black lettering and a rhinoceros-print seal. The recalled product was distributed nationwide through retail sellers and the company website from January 29, 2025 through May 25, 2026.

LOT
260327-4
RAINBOW TWIST
UPC 710154236506
ELECTRIC LEMONADE
UPC 710143236513
BERRY MOJITO
UPC 710154236544

The company announcement posted by FDA says DMAA can raise blood pressure and may lead to cardiovascular problems including heart attack, shortness of breath and chest tightening.

WHAT TO DO

Match the product, container size, lot, flavor and UPC. Follow the company's recall and return instructions, and contact a qualified clinician if you used the product or experienced symptoms that may be related to it. Chest pain, severe shortness of breath or other serious symptoms require urgent medical evaluation.

What remains unknown: The notice does not provide an expiration date, number of units sold or amount of DMAA detected. Leader Formulas reported no related adverse events as of October 7; that does not establish that exposure is safe. The recall applies to the specified lot, not automatically to every preworkout product.

FDA PUBLISH DATEOCT 01
2026
HIGH PRIORITY

FDA-POSTED COMPANY RECALL / COMPOUNDED INJECTABLE

Greenwich Rx compounded glutathione 200 mg/mL

Greenwich Rx voluntarily recalled ten lots of compounded glutathione, supplied in 10 mL multidose vials for subcutaneous injection, because of the potential for elevated endotoxin. The lots were distributed nationwide between June 26 and September 21, 2026.

  • 0060-062426-1: BUD 10/02/2026; 0060-062726-1: BUD 10/05/2026.
  • 0060-070926-1: BUD 10/17/2026; 0060-071426-1: BUD 10/22/2026; 0060-071426-2: BUD 10/22/2026.
  • 0060-072026-1: BUD 10/28/2026; 0060-072726-1: BUD 11/04/2026.
  • 0060-072926-1: BUD 11/06/2026; 0060-073126-1: BUD 11/08/2026; 0060-080426-1: BUD 11/12/2026.
WHAT TO DO

Match the pharmacy, concentration, vial size, lot and beyond-use date. If they match, contact Greenwich Rx, the dispensing pharmacy and the treating clinician promptly for recall instructions and medical guidance. Seek urgent care for severe symptoms.

What is known and unknown: The company reported two patients who required emergency-department care after intravenous administration of a product formulated for subcutaneous use. FDA's posting says elevated endotoxin can cause fever, low blood pressure, serious inflammatory reactions, anaphylactic shock and death. The notice does not establish the total number of administered vials, and it does not mean every glutathione product is contaminated.

FDA ALERT + RECALLSEP 21
2026
HIGH PRIORITY

FDA SAFETY ALERT / WEIGHT-LOSS SUPPLEMENTS

Niwali Tejocote products and Easy Forte Natural Fiber

FDA testing found that three supplements marketed as tejocote root or botanical weight-loss products contained toxic yellow oleander instead of the labeled ingredient. Yellow oleander contains cardiac glycosides and can cause severe or fatal neurologic, gastrointestinal and cardiovascular effects.

  • Niwali Tejocote Capsules: 90-count bottle; lot RM500925; best by 03/03/2028; sold through eBay.com and Everymarket.com.
  • Niwali Tejocote Pieces: 90-day supply; lot RM400925; best by 03/03/2028; UPC 1 99284 23789 6; sold through eBay.com and Everymarket.com.
  • Easy Forte Natural Fiber: purchased from the Jaola Store on Amazon.com. FDA did not publish a lot or expiration in the September 17 alert; the agency said it recommended a recall and Amazon removed the listing.
WHAT FDA SAYS

FDA advises consumers not to use products in its yellow-oleander alert and to contact a healthcare provider immediately if they have taken one, even if use was not recent. For the recalled Niwali products, match the exact product and lot, follow the company's return instructions and discuss possible exposure with a clinician. Seek emergency help for serious symptoms.

What remains known and unknown: Global Mix reported that five recalled Niwali units were sold and that no illnesses or adverse events had been reported to the company as of September 21. That does not establish safety. FDA says its broader surveillance of botanical weight-loss products is ongoing, and other products may be added to the alert.

FDA PUBLISH DATESEP 13
2026
HIGH PRIORITY

FDA-POSTED COMPANY RECALL / COMPOUNDED INJECTABLES

Centric Compounding glutathione, Myer's Cocktail and Tri-Immune Boost

Centric Compounding voluntarily recalled six lots nationwide after the products were compounded with a glutathione active ingredient containing elevated endotoxin. The products reached patients through home delivery and were also delivered to prescribers.

GLUTATHIONE
200 mg/mL, 30 mL vial
MYER'S COCKTAIL
30 mL vial
TRI-IMMUNE BOOST
30 mL vial
REASON
Elevated endotoxin
  • Glutathione: lot 062326:B, BUD 8/7/26; lot 070826:A, BUD 8/22/26; lot 072726:D, BUD 9/25/26.
  • Myer's Cocktail: lot 070226:D, BUD 8/16/26; lot 072126:A, BUD 9/4/26.
  • Tri-Immune Boost: lot 071626:B, BUD 8/30/26.
WHAT TO DO

Match the product, lot and beyond-use date on the vial. If they match, contact Centric Compounding, the dispensing pharmacy and the prescribing clinician promptly for recall instructions and clinical guidance. Seek urgent medical care for severe symptoms.

What FDA posted: The company reported nine cases involving fever, chills, chest pain, nausea or vomiting, headache and/or malaise. The recall notice says elevated endotoxin in injectable products can cause serious inflammatory reactions, low blood pressure, anaphylactic shock and death. The notice does not establish how many recalled vials were administered or the outcome of every report.

FDA PUBLISH DATESEP 15
2026
HIGH PRIORITY

FDA-POSTED COMPANY RECALLS / SEXUAL-ENHANCEMENT SUPPLEMENTS

A&P Creations X10 and biQ-FEL

A&P Creations voluntarily recalled identified lots of two liquid supplements after FDA laboratory analysis found undeclared sildenafil and tadalafil. These are prescription-drug ingredients, and undeclared exposure can be especially dangerous for people taking nitrate medicines because blood pressure may fall to unsafe levels.

  • X10: seven 15 mL red sachets in a red-and-gold box, UPC 7708075247094. Lots F090824LN16 (exp. 08/2026), F170325LN19 (exp. 03/2027) and F300326LN28 (exp. 03/2028).
  • biQ-FEL: 500 mL liquid bottle. Lots biQ-f001-06-25 (exp. 05/06/27) and biQ-003-01-26 (exp. 01/01/28; barcode 7709799120663).
WHAT TO DO

Check the exact product, packaging, lot and expiration. If they match, contact the seller, manufacturer and a qualified clinician for recall and health guidance—particularly if you use nitrates or experienced symptoms.

What remains known and unknown: The products were sold through Amazon, Walmart.com and naturefuel.us. The company reported no adverse events associated with either recall as of September 14. That does not establish that exposure is safe, and these recalls do not apply to every sexual-wellness supplement.

CLASS I RECALL / CATCH-UPSEP 08
2026
HIGH PRIORITY

FDA-POSTED COMPANY RECALL / PRESCRIBED SLEEP-APNEA DEVICE

BMC Luna G3 APAP, model LG3600

FDA classified a firmware defect as a Class I recall, its most serious device-recall category. Under a specific combination of high pressure, respiratory rate and peak flow, affected devices can display an error and shut down, interrupting prescribed therapy.

MODEL
LG3600
AFFECTED FIRMWARE
G3-2.00.76
CORRECTED VERSION
G3-2.00.77
UDI
06948538363331 / 06948538365892
WHAT TO DO

Check the model, serial number and firmware using the manufacturer's recall lookup, then contact the prescribing clinician and durable-medical-equipment provider to confirm whether the device is affected and arrange the appropriate replacement pathway. Do not change prescribed sleep-apnea therapy without clinical guidance.

Scope and limits: BMC retrospectively reported 20,160 devices, most of which had already been upgraded at the importer's warehouse; the company later estimated that up to 196 units may still carry the affected firmware. FDA's posting says no complaints or serious adverse-event reports had been received. This alert applies to the specified model, firmware and affected serial numbers—not every Luna or APAP device.

FDA COMMUNICATIONSEP 01
2026
HIGH PRIORITY

FDA BOXED WARNING / PRESCRIPTION IV IRON

Injectafer (ferric carboxymaltose injection)

FDA approved a boxed warning—the agency's most prominent safety warning—for ferric carboxymaltose injection, currently marketed as Injectafer, because symptomatic hypophosphatemia continues to be reported despite earlier label warnings.

PRODUCT
Ferric carboxymaltose injection
BRAND
Injectafer
RISK
Symptomatic hypophosphatemia
ACTION
Boxed warning added
WHAT FDA SAYS

Patients should report new or worsening muscle weakness or pain, fatigue, bone or joint pain, or confusion to their healthcare provider. FDA recommends phosphate monitoring for patients at risk of low phosphate and for anyone receiving a repeat course within three months. Treatment decisions belong with the prescribing clinician.

What remains uncertain: This is a labeling change, not a recall, and it does not mean every recipient will develop low phosphate. FDA's review found reports after both single and multiple infusions; serious outcomes included hospitalization, prolonged phosphate replacement, osteomalacia and fractures. FDA also found phosphate testing in fewer than 20% of administration episodes in its Sentinel analysis. Individual risk and symptoms require clinical assessment.

FDA PUBLISH DATEAUG 31
2026
HIGH PRIORITY

FDA-POSTED COMPANY RECALL / WEIGHT-LOSS SUPPLEMENT

Lipofit Extreme 2.0 Fat Burner

Ana Salazar Modela Tu Cuerpo Inc. voluntarily recalled one lot nationwide after FDA laboratory testing found undeclared fluoxetine in the daytime tablets and undeclared 2,4-dinitrophenol, or DNP, in the nighttime tablets. The product was marketed as a dietary supplement and sold directly to U.S. consumers online.

PRODUCT
AM and PM tablets
LOT
25M12F
EXPIRATION
09/2027
REASON
Undeclared fluoxetine and DNP
WHAT THE RECALL SAYS

The company announcement posted by FDA directs people with the affected lot to stop using it, keep it separated from children and others, and contact the company for disposition instructions. Do not sell, give away or transfer the product. Contact a clinician if you have experienced symptoms or problems that may be related to its use.

Why this matters: Fluoxetine is a prescription-drug ingredient. DNP is a toxic substance that is not FDA-approved for any use and is illegally marketed for weight loss. The recall notice describes potentially life-threatening cardiac, neurologic and overheating risks. No known adverse events had been reported to the company when the notice was posted; that does not establish that exposure is safe. This alert applies to the identified product and lot.

FDA PUBLISH DATEAUG 24
2026
HIGH PRIORITY

FDA-POSTED COMPANY RECALL / PRESCRIPTION DRUG

Vitruvias Thyroid Tablets USP 30 mg

Vitruvias Therapeutics voluntarily recalled one lot after testing confirmed the potential for the tablets to be superpotent. The FDA notice says excess thyroid hormone can cause hyperthyroid symptoms and may create greater risk for older adults, pregnant patients and infants.

LOT
504950
EXPIRATION
9/30/2026
NDC
69680-166-00
REASON
Potential superpotency
WHAT TO DO

Check the manufacturer, strength, lot and expiration on the bottle. If they match, contact the dispensing pharmacy or prescribing clinician. The recall notice specifically says patients should not discontinue the medicine without contacting their healthcare provider for guidance or a replacement prescription.

What we know: No adverse events known to be related to this recall had been reported to Vitruvias when the notice was posted. That does not change the need to verify affected bottles.

FDA PUBLISH DATEAUG 20
2026
HIGH PRIORITY

FDA-POSTED COMPANY RECALL / COMPOUNDED INJECTABLE

Optimal Balance Pharmacy compounded glutathione injection

Optimal Balance Pharmacy voluntarily recalled one lot of compounded glutathione after pharmacy testing identified elevated bacterial endotoxin. The affected product was distributed to consumers in multiple states, including Florida.

STRENGTH
200 mg/mL
PACKAGE
30 mL multi-dose vial
LOT
LG342009076
EXPIRATION
10/4/2026
WHAT THE RECALL SAYS

The company recall posted by FDA directs affected patients to stop using and quarantine the recalled product, contact Optimal Balance Pharmacy for retrieval, and contact the prescribing clinician if symptoms or problems may be related to its use.

Reported reactions: Fever, chills, severe headache, nausea, vomiting, pain and symptoms consistent with an allergic reaction. The notice also describes potentially serious endotoxin-related risks. This is a specific product-lot recall—not evidence that every glutathione product is contaminated.

FDA investigation update — August 27: FDA said it was aware of at least 30 patients with adverse events after IV glutathione made by different compounding pharmacies using Medisca dietary-supplement-grade glutathione, lot 229536. FDA said dietary-supplement-grade material is not appropriate for injectable drugs and that its investigation remains active. The full number of affected products, pharmacies and patients is not yet known.

02 / REGULATORY WATCH

Meaningful changes—
with the limits intact.

FDA GENERIC APPROVALOCT 19
2026

REGULATORY FACT / NOT A PRICE OR SUPPLY GUARANTEE

First generic once-weekly combined menopause patch

FDA approved Zydus Pharmaceuticals’ estradiol and levonorgestrel transdermal system as the first generic of Climara Pro.

The once-weekly patch delivers estradiol 0.045 mg per day and levonorgestrel 0.015 mg per day. FDA says it is therapeutically equivalent to Climara Pro and is approved for women with an intact uterus to treat moderate-to-severe vasomotor symptoms due to menopause and to help prevent postmenopausal osteoporosis.

  • This is a combined estrogen-progestogen patch—not an estrogen-only patch.
  • The progestogen component is included to reduce the risk of endometrial hyperplasia in people with a uterus.
  • Hormone therapy still requires an individualized review of symptoms, uterus status, medical history, contraindications and treatment goals.
  • FDA directed availability questions to the manufacturer; the announcement did not provide a U.S. launch date, retail price or pharmacy-level inventory.

What remains unknown: Generic approval may increase competition, but it does not guarantee immediate local availability, a particular out-of-pocket price or that this formulation is appropriate for an individual patient.

PROFESSIONAL GUIDELINEOCT 15
2026

ESTABLISHED GUIDANCE / INDIVIDUALIZED CARE

ACOG updates menopause symptom management

ACOG’s new guideline replaces its 2014 practice bulletin and addresses vasomotor symptoms, menopause-related sleep disturbance and mood symptoms.

The guideline strongly recommends systemic menopausal hormone therapy for vasomotor symptoms and related sleep disturbance in people without contraindications. It also recommends SSRIs or SNRIs and neurokinin-receptor antagonists for people who do not want hormone therapy or should not use it.

  • When hormone therapy is selected, ACOG recommends starting before age 60 or within 10 years of natural menopause in people without contraindications.
  • Shared decision-making should account for symptoms, age, time since menopause and baseline cardiovascular, breast-cancer and venous-thromboembolism risks.
  • CBT, mindfulness, exercise, clinical hypnosis and acupuncture receive conditional recommendations for selected symptoms; the evidence does not support phytoestrogens or herbal supplements for these uses.
  • The guideline does not replace evaluation of persistent or unscheduled bleeding and does not cover every menopause concern; separate genitourinary-syndrome guidance is expected later.

What this does not mean: The guidance does not make one treatment appropriate for everyone. Choice of hormonal, nonhormonal or nonpharmacologic care remains individualized and should be reviewed with a qualified clinician.

FDA RESEARCH REQUESTOCT 05
2026

REGULATORY FACT / NOT AN APPROVAL

FDA seeks input on early-phase ibogaine research

The agency is asking how first-in-human and early clinical studies should be designed safely. It has not approved ibogaine or concluded that it is effective.

FDA opened a public request for information focused on study design, dose selection, eligibility, cardiac and neurologic monitoring, stopping rules and independent safety oversight. The request notes serious cardiac and neurologic concerns and follows federal interest in research for opioid use disorder and post-traumatic stress disorder.

  • This is a research-policy step—not drug approval, prescribing guidance or evidence of clinical benefit.
  • FDA is specifically seeking safeguards for early trials because significant risks remain.
  • The agency said an early-phase investigational study of noribogaine for alcohol use disorder may proceed; that does not make either compound an approved treatment.
  • Public comments are due November 20, 2026.

What remains unknown: Safe dosing, patient selection, effectiveness and the overall benefit-risk profile have not been established. Unregulated products or clinics are not validated by this announcement.

FDA AVAILABILITY UPDATESEP 03
2026

REGULATORY FACT / NOT A RECALL

Estradiol transdermal patches

FDA says access to a usual brand or product may vary as demand rises, but estradiol patches remain available.

FDA said it is working with all six manufacturers after reports that some patients have had difficulty readily accessing their usual estradiol transdermal patch. The agency reported that U.S. supply of FDA-approved patches nearly doubled over the preceding year, while availability can still differ by pharmacy and location.

  • This is an availability update—not a recall and not a statement that every estradiol patch is in nationwide shortage.
  • FDA attributes the access pressure to increased demand and says manufacturers are increasing production and capacity.
  • If a usual patch is unavailable, FDA advises contacting the pharmacist and healthcare provider about appropriate FDA-approved options.
  • Patients should not stop or change medication without guidance from their healthcare provider.

What remains unknown: FDA did not provide brand-by-brand, dose-by-dose or local inventory data, so this notice cannot predict whether a particular pharmacy will have a specific product.

FDA AUTHORIZATIONAUG 25
2026

REGULATORY FACT / NOT A CONSUMER WELLNESS PICK

Abbott Libre Duo 10 Day

The first U.S. wearable authorized to continuously monitor both glucose and ketones.

FDA authorized the system for people age 2 and older living with diabetes. It measures glucose and ketones in interstitial fluid every minute during its 10-day wear period and can provide alerts when ketones reach a concerning threshold.

  • It is designed around diabetes safety and earlier recognition of rising ketones that may precede diabetic ketoacidosis.
  • FDA says ketone information should be interpreted alongside glucose readings and symptoms.
  • It is not the same product category or use case as Abbott Lingo or Dexcom Stelo, which appear in our OTC wellness-CGM guide.
  • U.S. consumer pricing and launch availability were not provided in the FDA announcement reviewed for this update.

THE MODERN BIO STANDARD

Regulatory facts are not product endorsements.

This page is educational and does not replace product labeling, recall instructions, diagnosis or individualized medical care. If a product identifier matches—or if you have concerning symptoms—contact the appropriate pharmacy, manufacturer or qualified clinician. Seek urgent care for potentially serious symptoms.